… ProQR Announces Publication in Nature Medicine for Sepofarsen … & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a company dedicated … vision,” said Aniz Girach, MD, Chief Medical Officer of ProQR, “The visual field improvements observed indicate that …
… ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for … LEIDEN, the Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research and Development at ProQR. “Now that the study is initiated we expect to dose the …
… ProQRR&D day Highlights Progress on Pipeline and Introduces … RNA Technology Key program features and updates: ProQR to host an R&D day in New York today, June 15, from … the nasal potential difference (NPD) study for QR-010, ProQR’s lead molecule for CF that is studied in two clinical …
… ProQR Therapeutics Announces Transaction Completed for Théa … on commercial sales in the US and EU Transaction supports ProQR’s strategic focus on its proprietary Axiomer ® RNA … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Announces Amendment to Convertible Debt Financing … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the … said Smital Shah, Chief Business and Financial Officer of ProQR. “If fully drawn down, this facility extends our cash …